The present invention relates to novel analogs of choline and methods of
use or treatment of neurodegenerative disorders and/or conditions such as
Parkinson's disease, Huntington disease, Alzheimer's disease and related
disorders such as amyotrophic lateral sclerosis, spinal muscular atrophy,
Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's
disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease
(mad cow disease), dementia with Lewy bodies, schizophrenia,
paraneoplastic cerebellar degeneration and neurodegenerative conditions
caused by stroke. The present compounds are effective to treat any
neurological condition where acetylcholine transmission neurons and their
target cells are affected. Compounds according to the present invention
are effective to alleviate and/or reverse the effects of a
neurodegenerative condition, prevent further deterioration and/or enhance
cognition and memory in patients suffering from neurodegenerative
disorders, especially Alzheimer's disease.
